Gilead Sciences and AstraZeneca in Hyperlipidemias
Their studies and programs in Hyperlipidemias, as the condition page counts them: each program at the phase its studies here reached, with their next primary completion here. Counts, not rankings.
At a glance
Studies each sponsor leads that are filed under Hyperlipidemias, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Gilead Sciences | AstraZeneca |
|---|---|---|
| Phase 1 | – | AstraZeneca: 2 of its 3 programs at phase 1
|
| Phase 2 | – | 00% |
| Phase 3 | – | 00% |
| Approved, new studies | – | AstraZeneca: 1 of its 3 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences0 readouts · 0 phase 3 | · | · | · | · | · | · | · | · | · | · | · | · |
| AstraZeneca0 readouts · 0 phase 3 | · | · | · | · | · | · | · | · | · | · | · | · |
Changed in the last 90 days
Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Gilead Sciences
No programs read for this company.
AstraZeneca
New programs 0
None
Study stopped 0
None
Primary completion later 0
None
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- Within Hyperlipidemias: a program counts when one of its company’s studies of the last two years names Hyperlipidemias as its condition, as the condition page counts it; its phase and next readout are its studies’ here. Stage, biomarker and line of therapy are not read yet.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.